The US Food and Drug Administration has approved an expanded indication for Eli Lilly and Company’s and Boehringer Ingelheim’s (BI) combination product, Synjardy (empagliflozin and metformin hydrochloride) tablets to include treatment-naïve adults with Type 2 diabetes (T2D). The drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D when treatment with both empagliflozin and metformin is appropriate.

Synjardy is part of Lilly’s and BI diabetes alliance that was formed in 2011.

Synjardy consists of empagliflozin, a sodium glucose co-transporter-2 inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney, and metformin, a commonly prescribed initial treatment for T2D, which lowers glucose production by the liver and its absorption in the intestine.

Source: Eli Lilly and Company